Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (21)	1/16/1999 8:39:00 PM
From: yosi s	Read Replies (1) \| Respond to of 423

In regards to Memantine: What I am saying that If a drug had significant efficacy, with a tract record of 10 years., why a phase 3 trial in Europe. I do not understand. As for Philosophy on investing, You are going for a me too drug, with broader indication. I rather go for a novel therapeutic. Yes the risk is higher. But so is the reward. As for Pharmos. Yes I do own a big chunk of it, but I was not plugging it at this time. as no new info is out. By the way HU 211 also work as NMDA antagonist . and unlike others it does not cause problem with hypotension. ( but that is not its sole mechanisme of action.)